Literature DB >> 14522101

Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).

Karin Seifert1, Sangeeta Matu, F Javier Pérez-Victoria, Santiago Castanys, Francisco Gamarro, Simon L Croft.   

Abstract

Leishmania donovani promastigote lines resistant to hexadecylphosphocholine (HePC, miltefosine) at 2.5, 5.0, 10.0, 20.0 and 40.0 microM were developed in vitro by continuous step-wise drug pressure. The 40 microM line was 15 times more resistant to HePC than the wild-type clone and showed cross-resistance to the ether lipid ET-18-OCH3 (edelfosine) but not to the standard anti-leishmanial drugs. Resistance was stable up to 12 weeks in drug-free culture medium. No amplification of specific genes, including the multidrug resistance P-glycoprotein gene, could be detected in the resistant parasites.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14522101     DOI： 10.1016/s0924-8579(03)00125-0

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


  60 in total

1.  Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to Miltefosine by inhibiting drug efflux.

Authors:  José M Pérez-Victoria; Fernando Cortés-Selva; Adriana Parodi-Talice; Boris I Bavchvarov; F Javier Pérez-Victoria; Francisco Muñoz-Martínez; Mathias Maitrejean; M Paola Costi; Denis Barron; Attilio Di Pietro; Santiago Castanys; Francisco Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.

Authors:  Karin Seifert; Simon L Croft
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 3.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani.

Authors:  Arpita Kulshrestha; Vasundhra Bhandari; Rupkatha Mukhopadhyay; V Ramesh; Shyam Sundar; Louis Maes; Jean Claude Dujardin; Syamal Roy; Poonam Salotra
Journal:  Parasitol Res       Date:  2012-12-13       Impact factor: 2.289

5.  Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum.

Authors:  S Hendrickx; G Boulet; A Mondelaers; J C Dujardin; S Rijal; L Lachaud; P Cos; P Delputte; L Maes
Journal:  Parasitol Res       Date:  2014-03-11       Impact factor: 2.289

6.  Drug resistance in leishmaniasis.

Authors:  Jaya Chakravarty; Shyam Sundar
Journal:  J Glob Infect Dis       Date:  2010-05

7.  Nelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotes.

Authors:  Pranav Kumar; Robert Lodge; Nathalie Trudel; Michel Ouellet; Marc Ouellette; Michel J Tremblay
Journal:  PLoS Negl Trop Dis       Date:  2010-03-30

8.  Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes.

Authors:  Juan Román Luque-Ortega; Luis Rivas
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

9.  Possible mechanism of miltefosine-mediated death of Leishmania donovani.

Authors:  Navin K Verma; Chinmoy S Dey
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 10.  Drug resistance in visceral leishmaniasis.

Authors:  Helena C Maltezou
Journal:  J Biomed Biotechnol       Date:  2009-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.